Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Beneficial effect by Xanthine oxidase inhibitor on endothelial function beyond Uric Acid trial

Next Previous
Trial Profile

Beneficial effect by Xanthine oxidase inhibitor on endothelial function beyond Uric Acid trial

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 16 Oct 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Topiroxostat (Primary) ; Febuxostat
  • Indications Hyperuricaemia
  • Focus Therapeutic Use
  • Acronyms BEYOND-UA-trial

Most Recent Events

  • 05 Jan 2021 Primary endpoint has not been met. (Changes in CAVI from baseline to 24 weeks), according to results published in the Journal of Clinical Hypertension (Greenwich).
  • 05 Jan 2021 Status changed from active, no longer recruiting to completed, according to Results published in the Journal of Clinical Hypertension (Greenwich).
  • 05 Jan 2021 Results published in the Journal of Clinical Hypertension (Greenwich)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top